Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Documents similaires

• Superior benefits of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease: A cohort study
  par: Hsiao‐Ling Chen, et autres
  Publié: (2024)
• Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
  par: Tsung‐Hua Shen, et autres
  Publié: (2024)
• Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study
  par: Ya‐Hui Yu, et autres
  Publié: (2024)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  par: Ryo Suzuki, et autres
  Publié: (2025)
• Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study
  par: Jenny Dimakos, et autres
  Publié: (2024)